Rehashing the "Rare Earth Playbook" to Establish a Monopoly? The U.S. is Relentlessly Attacking Chinese Pharmaceuticals, with a Sinister Hidden Agenda Behind the Scenes

(Source: Defense Situation)

Recently, the U.S. Congress has come up with a new stunt. A hearing targeting China’s pharmaceutical industry has caused a huge stir. The lawmakers are furious, pointing at charts on PPT slides, shouting at the top of their lungs: “China is about to monopolize the global medical supply chain!” “This is a national security crisis!”

Sound familiar? Too familiar! This tactic is basically a copy of the “rare earth threat” hype from back then, directly transplanted into the medical field. But this time, their target has shifted from underground minerals to life-saving medicines. It’s not about concern over dependence; it’s clear they’re panicked by China’s rise!

U.S. politicians claim they want to “de-risk,” but secretly they’re plotting to “block the choke point.” They’re trying to replicate the “rare earth script,” aiming to label Chinese pharmaceuticals as “monopolistic” to justify future sanctions and suppression. But their scheme is not only loud but also extremely insidious!

First layer of insidiousness: data fabrication, making things up out of thin air. At the hearing, lawmakers casually claimed China controls 90% of the global raw drug materials. But what’s the truth? According to authoritative data, China does have advantages in some specialty raw medicines, but its overall share is far from that figure. This exaggeration of “advantage” into “monopoly” is just like back then when they claimed China controlled “absolute” processing of rare earths. They deliberately confuse concepts and stir panic to deceive the public and rally allies.

Second layer of insidiousness: blaming China for their own mess. Is the U.S. pharmaceutical supply chain really problematic? Yes! And it’s a big problem! Decades of hollowing out the industry, severe lack of domestic capacity—when the slightest disturbance occurs, they can’t even supply basic antibiotics. This is the consequence of their long-term neglect of manufacturing and over-financialization. But instead of reflecting on their failures, they blame China as if crushing China would instantly revive their pharmaceutical factories. Isn’t that just closing their eyes and stealing a bell?

Third layer of insidiousness: double standards and selective suppression. The most ridiculous part is that the U.S. claims to support a “free market,” yet they are aggressively blocking Chinese pharmaceutical companies from normal investments and mergers. Whenever a Chinese company wants to acquire a foreign drug factory or expand capacity, they immediately halt it citing “national security.” So only they can buy and sell? We’re not allowed to develop? This isn’t fair competition; it’s outright bullying!

They can’t succeed with the rare earth script in pharmaceuticals! When they tried to blockade China’s rare earths, what happened? China’s technology became more advanced as they faced restrictions, and the global supply chain became even more dependent on China. Now they want to repeat the same old trick against China’s pharmaceutical industry—dream on! China’s pharmaceutical industry relies on decades of technological accumulation, a complete industrial chain, and engineering talent dividends, not some “illegitimate means.”

No matter how loud their schemes are, they can’t hide the collapse of their own industrial logic. Relying on re-enacting the “rare earth script” to contain China is just a futile effort. China’s pharmaceutical innovation will not stop because of these “insidious schemes”; instead, it will become more stable and far-reaching through storms and challenges!

Part of the material sourced from: Observer Network

Massive information, precise analysis, all on Sina Finance APP